Literature DB >> 33588862

A novel prognostic prediction model based on seven immune-related RNAs for predicting overall survival of patients in early cervical squamous cell carcinoma.

Rui Qin1, Lu Cao1, Cong Ye1, Junrong Wang2, Ziqian Sun3.   

Abstract

BACKGROUND: In this study, we aimed to mine immune-related RNAs expressed in early cervical squamous cell carcinoma to construct prognostic prediction models.
METHODS: The RNA sequencing data of 309 cervical squamous cell carcinoma (CSCC) cases, including data of individuals with available clinical information, were obtained from The Cancer Genome Atlas (TCGA) database. We included 181 early-stage CSCC tumor samples with clinical survival and prognosis information (training dataset). Then, we downloaded the GSE44001 gene expression profile data from the National Center for Biotechnology Information Gene Expression Omnibus (validation dataset). Gene ontology annotation and the Kyoto Encyclopedia of Genes and Genomes pathway analyses were used to analyze the biological functions of differentially expressed immune-related genes (DEIRGs). We established protein-protein interactions and competing endogenous RNA networks using Cytoscape. Using the Kaplan-Meier method, we evaluated the association between the high- and low-risk groups and the actual survival and prognosis information. Our univariate and multivariate Cox regression analyses screened for independent prognostic factors.
RESULTS: We identified seven prognosis-related signature genes (RBAKDN, CXCL2, ZAP70, CLEC2D, CD27, KLRB1, VCAM1), the expression of which was markedly associated with overall survival (OS) in CSCC patients. Also, the risk score of the seven-gene signature discripted superior ability to categorize CSCC patients into high-risk and low-risk groups, with a observablydifferent OS in the training and validation datasets. We screened two independent prognostic factors (Pathologic N and prognostic score model status) that correlated significantly by univariate and multivariate Cox regression analyses in the TCGA dataset. To further explore the potential mechanism of immune-related genes, we observed associated essential high-risk genes with a cytokine-cytokine receptor interaction.
CONCLUSIONS: This study established an immune-related RNA signature, which provided a reliable prognostic tool and may be of great significance for determining immune-related biomarkers in CSCC.

Entities:  

Keywords:  Early cervical squamous cell carcinoma; Immune-related RNAs signature; Prognostic prediction model

Year:  2021        PMID: 33588862      PMCID: PMC7885601          DOI: 10.1186/s12920-021-00885-3

Source DB:  PubMed          Journal:  BMC Med Genomics        ISSN: 1755-8794            Impact factor:   3.063


  41 in total

1.  Cytoscape: a software environment for integrated models of biomolecular interaction networks.

Authors:  Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker
Journal:  Genome Res       Date:  2003-11       Impact factor: 9.043

2.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

3.  L1 penalized estimation in the Cox proportional hazards model.

Authors:  Jelle J Goeman
Journal:  Biom J       Date:  2010-02       Impact factor: 2.207

4.  Identification of prognostic risk factors of acute lymphoblastic leukemia based on mRNA expression profiling.

Authors:  C Li; L Kuang; B Zhu; J Chen; X Wang; X Huang
Journal:  Neoplasma       Date:  2017       Impact factor: 2.575

5.  AKIP1 promotes angiogenesis and tumor growth by upregulating CXC-chemokines in cervical cancer cells.

Authors:  Wenying Zhang; Qiongwei Wu; Chao Wang; Longtao Yang; Ping Liu; Chengbin Ma
Journal:  Mol Cell Biochem       Date:  2018-03-08       Impact factor: 3.396

6.  Identification of a 26-lncRNAs Risk Model for Predicting Overall Survival of Cervical Squamous Cell Carcinoma Based on Integrated Bioinformatics Analysis.

Authors:  Yu Mao; Zhanzhao Fu; Lixin Dong; Yue Zheng; Jing Dong; Xin Li
Journal:  DNA Cell Biol       Date:  2019-01-30       Impact factor: 3.311

7.  Human Papillomavirus E6/E7 and Long Noncoding RNA TMPOP2 Mutually Upregulated Gene Expression in Cervical Cancer Cells.

Authors:  Hongpeng He; Xiang Liu; Yue Liu; Mengmeng Zhang; Yongwei Lai; Yunpeng Hao; Qiutong Wang; Danyang Shi; Nan Wang; Xue-Gang Luo; Wenjian Ma; Tong-Cun Zhang
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

8.  Cluster analysis and display of genome-wide expression patterns.

Authors:  M B Eisen; P T Spellman; P O Brown; D Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

9.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nucleic Acids Res       Date:  2008-11-25       Impact factor: 16.971

10.  Chemokine (C-X-C motif) ligand 1 and CXCL2 produced by tumor promote the generation of monocytic myeloid-derived suppressor cells.

Authors:  Huifang Shi; Xiaoqing Han; Yingying Sun; Chao Shang; Min Wei; Xueqing Ba; Xianlu Zeng
Journal:  Cancer Sci       Date:  2018-11-08       Impact factor: 6.716

View more
  3 in total

1.  ZAP70 Activation Compensates for Loss of Class IA PI3K Isoforms Through Activation of the JAK-STAT3 Pathway.

Authors:  Melike Demir; Onur Cizmecioglu
Journal:  Cancer Diagn Progn       Date:  2022-05-03

2.  A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.

Authors:  Hui-Hui Xu; Hui-Li Wang; Tong-Jin Xing; Xue-Quan Wang
Journal:  Front Immunol       Date:  2022-07-18       Impact factor: 8.786

3.  Construction and validation of prognostic prediction established on N6-methyladenosine related genes in cervical squamous cell carcinoma.

Authors:  Danxia Chen; Wenhao Guo; Hailan Yu; Jianhua Yang
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.